SEC filing summary
Filing identity: The supplied filing is Point Capital, Inc.’s Form 10-Q for the quarter ended September 30, 2018—not a filing identified as Silo Pharma, Inc. The summary below reflects the filing text provided.
Business context and reporting period
Point Capital reported as a business development company and investment company until September 29, 2018, when it withdrew its BDC election. It plans to operate primarily as a footwear and apparel developer. The company acquired the NFID unisex footwear brand at quarter-end; the filing says product development would continue toward a full launch. Reporting is unusual: prior periods use investment-company accounting, while corporation accounting applies beginning September 29, 2018; the company did not restate earlier periods.
Financial results and position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Investment income | 2018: $18; 2017: $6,504 | 2018: $44; 2017: $20,478 |
| Operating expenses | 2018: $81,182; 2017: $98,159 | 2018: $292,145; 2017: $321,533 |
| Net loss/income from operations | 2018: loss of $198,162; 2017: loss of $519,143 | 2018: loss of $496,527; 2017: income of $149,652 |
- No footwear-product revenue is reported; reported income was primarily investment interest.
- Cash and cash equivalents were $626,115, up from $294,591 at December 31, 2017. Nine-month operating cash flow was positive $431,524; investing cash flow was negative $100,000, reflecting the initial note advance. Ending cash was $626,115.
- Total assets were $1,435,248, including $391,698 of fair-value equity investments, $12,767 of investments carried at cost, a $100,000 note receivable, and $282,500 of intangible assets and goodwill. Current liabilities were $28,733. No debt is reported; $400,000 of redeemable preferred stock is classified as temporary equity.
- Stockholders’ equity was $1,006,515. Common shares outstanding increased by 2,000,000 to 52,082,441 through the NFID asset acquisition. Reported net asset value per common share was $0.02.
Material changes, outlook, and risks
- NFID assets were acquired for 2,000,000 common shares valued at $300,000 ($0.15 per share). The allocation included a $105,295 brand ambassador agreement, $29,440 of trademarks, and $147,765 of goodwill. The agreement includes a 7% royalty on net sales and a $35,000 minimum payment; $17,500 remained payable January 27, 2019.
- The company entered a two-year, 6% secured note agreement with the seller for $200,000. It had funded $100,000 by September 30 and advanced the remaining $100,000 in October 2018. Principal is due at maturity in September 2020, with quarterly interest-only payments.
- Management said available cash should cover working capital needs for at least 12 months from the report date, but warned that NFID development and marketing may require additional capital. There were no financing agreements in place, and management could not assure profitability, positive cash flow, or access to financing; failure to raise funds could require curtailment of operations.
- The IDTY holding represented 100% of the fair-value investment portfolio and approximately 27.3% of total assets. The company was actively selling its shares, with proceeds intended for working capital, NFID development, or acquisitions. Investment values, liquidity, and potential sale proceeds are subject to market risk.
- The company lost RIC tax status after failing the diversification test and is subject to corporate income tax rates. Management reported disclosure controls and internal control over financial reporting were ineffective, citing material weaknesses including inadequate segregation of accounting duties and weaknesses in investment valuation and custody controls.
- The company reported no pending material legal proceedings, no defaults on senior securities, and no off-balance-sheet arrangements. It reported no material capital expenditure commitments.
Most important facts to verify
- Confirm issuer identity: the supplied document names Point Capital, Inc., not Silo Pharma, Inc.
- Reconcile investment gains and losses: the statements report nine-month realized loss of $101,715 and unrealized loss of $102,711, while MD&A also describes gross realized gains and a $569,187 write-down/reversal. The filing text does not clearly reconcile these components.
- Review valuation and sale assumptions for the concentrated IDTY holding and the $569,187 permanent write-down of nonmarketable securities.
- Assess the seller’s ability to repay the $200,000 secured note and confirm the collateral, subsequent funding, and collection terms.
- Evaluate NFID launch costs, royalty obligations, financing needs, and remediation of the disclosed material weaknesses in financial reporting controls.